Compare BNTC & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNTC | NEWT |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.3M | 395.5M |
| IPO Year | 2020 | N/A |
| Metric | BNTC | NEWT |
|---|---|---|
| Price | $12.34 | $11.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $27.67 | $14.00 |
| AVG Volume (30 Days) | ★ 173.1K | 162.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.34% |
| EPS Growth | ★ 80.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.45 |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $9.12 |
| 52 Week High | $17.15 | $14.91 |
| Indicator | BNTC | NEWT |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 38.53 |
| Support Level | $11.30 | $11.72 |
| Resistance Level | $12.75 | $12.41 |
| Average True Range (ATR) | 0.72 | 0.46 |
| MACD | 0.23 | -0.07 |
| Stochastic Oscillator | 66.15 | 30.26 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.